Author: Customer Service

KALDVIK AS (KLDVK) reports Operating income in Q1 amounted to EURm 36.5 (EURm 48.4), while the operating loss before fair value adjustment of biomass and production tax was EURm -26.4 (EURm 9.8).  Harvest amounted to 6,441 (6,383) tonnes in Q1 2026. Kaldvík AS maintains harvest guidance for 2026 to approximately 17,000 tonnes. The Q1 2026 quarterly update presentation is attached. Kaldvik AS publishes full financial statements semi-annually (half-year and annual reports). Webcast A webcast presentation of the Q1 2026 quarterly update will be held at 15:00 CEST (13:00 Icelandic time) on 1 June 2026. The presentation will be held in English by CEO Vidar Aspehaug and CFO Hjalti Hvítklett. A Q&A session will follow. The webcast can be accessed at: http://www.kaldvik.is/live Contact: Hjalti Hvítklett, CFO+298 221 222 (mobile) This information...

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reductionIMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinabilityIMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature MedicineThe data support Immatics’ strategy to combine IMA401 with IMA402 (PRAME bispecific) in lung cancer and potentially other...

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 31 May 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative...

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting. Key findings are detailed below. Oral Presentation: RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study; Date/Time: May 31, 2026, 9:12 AM CDT; Location: Arie Crown Theater; Abstract: 2504; Presenter: Joseph Sacco, PhD, MBChBThe Phase 1 first-in-human trial enrolled 85 heavily pretreated...

Results simultaneously published in The New England Journal of Medicine REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results will be presented during a late-breaking Plenary Session (LBA5) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting at 3:21 p.m. CDT today and were published today in The New England Journal of Medicine. RAS, a key growth control switch in human cells, is the primary oncogenic...

Nokia CorporationManagers’ transactions31 May 2026 at 13:00 EEST Nokia Corporation – Managers’ transactions (Hanrahan) Transaction notification under Article 19 of EU Market Abuse Regulation.____________________________________________Person subject to the notification requirementName: Hanrahan, VictoriaPosition: Other senior manager Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06Notification type: INITIAL NOTIFICATIONReference number: 158758/5/6____________________________________________Transaction date: 2026-05-26Venue: XNYSInstrument type: SHAREISIN: US6549022043Nature of the transaction: ACQUISITION Transaction details(1): Volume: 22713 Unit price: 16.0179 USD Aggregated transactions(1): Volume: 22713 Volume weighted average price: 16.0179 USD____________________________________________Transaction date: 2026-05-28Venue:...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition Consistent secondary endpoint results, including PSA progression and time to mCRPC, and safety profile reinforce broad clinical applicabilityPromising Phase 1 data for Novartis actinium-based RLT also presented, supporting two Phase 3 trials and reinforcing Novartis global RLT leadershipBasel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC; androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone in PSMA-positive metastatic...

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST         Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumoursData presented at 2026 ASCO® Annual Meeting show ODM-212 was well tolerated, with proteinuria being the most common treatment related adverse event (TRAE) ODM-212 showed early efficacy in Hippo pathway dysregulated tumours, such as mesothelioma and EHE (epithelioid hemangioendothelioma) A clinical development program is underway investigating ODM-212 as a monotherapy and in combination with standard of care treatments in various solid tumoursOrion Pharma today announced first Phase 1 results from the ongoing Phase 1/2 multi-site, open-label, first-in-human TEADES trial evaluating the safety, tolerability and preliminary efficacy of ODM-212,...

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumorsMILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including updated data for its EIK1001...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trialsMAINZ, Germany, and PRINCETON, USA,...